Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease
Nature Cardiovascular Research, 2026
Tinworth A., Yao P., Iona A., Pozarickij A., Von Ende A., Millwood I., Walters R., Clarke R., Bragg F., Chen Z.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD Environmental Health & Toxicology | Pathophysiology | Plasma | Olink Explore 3072/384 |
Abstract
Tobacco smoking increases the risk of multiple diseases, but the biological mechanisms involved remain incompletely understood. Here we characterize smoking-related protein profiles to identify potentially causal biomarkers mediating smoking’s effects. In European-ancestry populations, genetically predicted smoking exposures were significantly associated with levels of 93 (total: 2,922) proteins, including higher levels of asialoglycoprotein receptor 1 (ASGR1). The positive association of ASGR1 levels with ischemic heart disease (IHD) was supported by colocalization (posterior probability of hypothesis 4 = 0.91), and was estimated to explain 6.35% (95% confidence interval 2.61–10.09%, P = 8.77 × 10 −4 ) of smoking’s effects on IHD in two-step Mendelian randomization analyses. In network analyses, genetically predicted ASGR1 levels were inversely associated with plasma levels of more than 100 proteins, including growth arrest-specific 6, with all these proteins having rs55714927 (that is, a cis -protein quantitative trait locus for ASGR1) as a trans -protein quantitative trait locus. Sensitivity analyses in never-smokers identified a nonstatistically significant residual association between ASGR1 and IHD, which is consistent with possible horizontal pleiotropy, with body mass index implicated as a potential contributing pathway.